Drug-Eluting Stents for Treatment of Peripheral Artery Disease

Endovascular intervention is a mainstay treatment of peripheral artery disease (PAD) in addition to aggressive risk factor modification and exercise programs in patients with favorable anatomy or in those who are considered too high risk for surgical intervention. Treatment with percutaneous translu...

Full description

Saved in:
Bibliographic Details
Published in:American journal of cardiovascular drugs : drugs, devices, and other interventions devices, and other interventions, 2018-06, Vol.18 (3), p.175-180
Main Authors: Abdullah, Kazeen, Bou Dargham, Bassel, Steinbrecher, Micah, Sun, Bo, Huiqiang, Zhao, Khalili, Houman, Brilakis, Emmanouil S., Banerjee, Subhash
Format: Article
Language:English
Subjects:
Amputation
Angioplasty
Cardiology
Cardiovascular disease
Clinical trials
Copyright
Inflammation
Ischemia
Medicine
Medicine & Public Health
Pharmacology/Toxicology
Pharmacotherapy
Review Article
Stents
Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Endovascular intervention is a mainstay treatment of peripheral artery disease (PAD) in addition to aggressive risk factor modification and exercise programs in patients with favorable anatomy or in those who are considered too high risk for surgical intervention. Treatment with percutaneous transluminal angioplasty (PTA) and bare metal stents (BMS) has been limited by high rates of in-stent restenosis (ISR) requiring repeat revascularization. Drug-eluting stents (DES), developed and designed to reduce ISR, offer a promising solution to the current challenges in endovascular management of PAD. Several randomized clinical trials have shown improved short- and mid-term outcomes with DES as compared with both PTA and BMS. Herein we provide an up-to-date review of the current literature on DES use in PAD.
ISSN:1175-3277
1179-187X
DOI:10.1007/s40256-018-0265-4